Wall Street Associates’s Enanta Pharmaceuticals ENTA Stock Holding History

Wall Street Associates’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$342K	Hold	10,200	–	–	0.23%	156
2016 Q3	$271K	Hold	10,200	–	–	0.09%	201
2016 Q2	$225K	Hold	10,200	–	–	0.09%	207
2016 Q1	$300K	Hold	10,200	–	–	0.12%	183
2015 Q4	$337K	Hold	10,200	–	–	0.09%	262
2015 Q3	$369K	Sell	10,200 -136,100	-93%	-$5.84M	0.07%	253
2015 Q2	$6.58M	Sell	146,300 -5,500	-4%	-$214K	0.62%	56
2015 Q1	$4.65M	Sell	151,800 -6,600	-4%	-$257K	0.44%	82
2014 Q4	$8.05M	Sell	158,400 -700	-0.4%	-$31.3K	0.77%	36
2014 Q3	$6.3M	Sell	159,100 -60,100	-27%	-$2.4M	0.65%	50
2014 Q2	$9.44M	Buy	219,200 +2,600	+1%	+$99.2K	0.81%	29
2014 Q1	$8.66M	Sell	216,600 -53,800	-20%	-$1.95M	0.71%	43
2013 Q4	$7.38M	Buy	270,400 +15,500	+6%	+$376K	0.6%	55
2013 Q3	$5.84M	Sell	254,900 -7,900	-3%	-$151K	0.54%	60
2013 Q2	$4.65M	Buy	+262,800	New	+$5.12M	0.47%	73

Other funds holding ENTA

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wall Street Associates's ENTA Position: Q4 2016 in Review

Wall Street Associates held its Enanta Pharmaceuticals (ENTA) position steady in Q4 2016 at 10,200 shares worth $342K. The position accounts for 0.23% of the portfolio, ranked #156.

Wall Street Associates first reported a position in ENTA in Q2 2013 and has held it in 15 quarters since. The position peaked at $9.44M in Q2 2014. 149 funds tracked by Wall St. Rank hold ENTA as of Q4 2016.

Wall Street Associates held 10,200 shares of Enanta Pharmaceuticals worth $342K as of Q4 2016.
Wall Street Associates left its Enanta Pharmaceuticals share count unchanged in Q4 2016.
Enanta Pharmaceuticals made up 0.23% of Wall Street Associates's portfolio in Q4 2016, its #156 holding.
Wall Street Associates first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
Wall Street Associates's Enanta Pharmaceuticals position peaked at $9.44M in Q2 2014.
149 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.